| Registrars: | Equiniti |
| Brands: | Lucozade, Horlicks, Ribena, Paxil, Seroxat |
| CEO: | Luke Miels |
| Chief Finance Officer: | Julie Brown |
| Independent Non-Executive Director: | Harry (Hal) C. Dietz |
| Independent Non-Executive Director: | Vishal Sikka |
| Independent Non-Executive Director: | Elizabeth (Liz) McKee Anderson |
| Independent Non-Executive Director: | Anne Beal |
| Non-Executive Chairman: | Jonathan Symonds |
| Senior Independent Non-Executive Director: | Charles Bancroft |
| Non-Executive Dir: | Gavin Screaton, Wendy Becker , Jeannie Lee , Hal Barron |
| Address: | 79 New Oxford Street, London, United Kingdom, WC1A 1DG |
| Phone: | +44 (0)20 8047 5000 |
| Website: | http://www.gsk.com/en-gb/ |
| Sector: | Pharma and Biotech(LSE) |
| Index: | techMARK, FTSE 100, FTSE 350, FTSE All-Share |
| Overseas Listings: | BATSLON:GSKL, NYSE:GSK |
| ISIN: | GB00BN7SWP63 |
| Currency | UK Pounds |
| Share Price | 2,165.00p |
| Change Today | 24.00p |
| % Change | 1.12 % |
| 52 Week High | 2,198.00p |
| 52 Week Low | 1,264.00p |
| Volume | 13,157,222 |
| Shares Issued | 4,076.08m |
| Market Cap | £88,247m |
| Beta | 0.84 |
| RiskGrade | 129 |
| Value | ![]() |
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth | ![]() |
|---|
| Strong Buy | 4 |
| Buy | 3 |
| Neutral | 13 |
| Sell | 3 |
| Strong Sell | 0 |
| Total | 23 |

| Latest | Previous | |
|---|---|---|
| Q4 | Q3 | |
| Ex-Div | 19-Feb-26 | 13-Nov-25 |
| Paid | 09-Apr-26 | 08-Jan-26 |
| Amount | 18.00p | 16.00p |
| Time | Volume / Share Price |
| 12:27 | 1,997,424 @ 2,170.00p |
| 12:27 | 1,997,424 @ 2,170.00p |
| 17:05 | 6,081 @ 2,165.00p |
| 16:35 | 9,028 @ 2,165.00p |
| 16:35 | 972 @ 2,165.00p |
You are here: research